Recursion Pharmaceuticals, Inc. (RXRX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and thank you for joining us. Before we begin, I'd like to remind everyone that today's discussion will include forward-looking statements. Next slide. Please refer to today's press release and our SEC findings filings for additional details. At Recursion, our mission is to decode biology to radically improve patient lives. and we do this by building transformational medicines with an AI-native product engine. Over the past year, we have reached an important inflection point. We are no longer just discussing the potential of our platform. We are demonstrating the ability of our AI-native product engine to generate differentiated programs and medicines. Just as a reminder, the engine you see on the left hand side is built as a continuous learning system. proprietary multimodal data created in our data factory powers frontier AI models. And these models then generate new hypotheses where every single prediction is tested experimentally. Each cycle strengthens both the engine and the products it creates. Ultimately, though, the measure of any engine is its output. So let's talk about that. First, our internal pipeline continues to mature. We now have five clinical stage programs, including REC 4881 and FAP, where we have generated some of the most promising clinical data in the company's history. Remember, in a disease with no approved therapies and a TAM of almost 10 billion. Second, we continue to make significant progress in our partnerships while learning from the best in the industry and also while validating our engine externally. Together with leading biopharma partners, we have generated more than 500 million in realized inflows while advancing differentiated programs with Sanofi and Roche Genentech. So today I'll share how we continue to...